An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic Leukemia
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Arsenic trioxide (Primary) ; Arsenic trioxide
- Indications Acute promyelocytic leukaemia
- Focus Pharmacokinetics
- Sponsors Syros Pharmaceuticals
- 01 Nov 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Jan 2024.
- 01 Nov 2023 Status changed from recruiting to suspended.
- 02 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Apr 2024.